S J Marcus1, R E Ware. 1. Duke Pediatric Sickle Cell Program, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract
PURPOSE: Fetal hemoglobin (HbF) is an important determinant in the clinical severity of patients with sickle cell disease. The physiologic decline in HbF parameters in a cohort of infants with sickle cell disease was investigated. PATIENTS AND METHODS: The percent HbF and F cells were quantitated, and the HbF per F cell was then calculated. One hundred thirty-eight blood samples from 44 infants with homozygous sickle cell anemia (HbSS) and 56 samples from 24 infants with sickle cell hemoglobin (HbSC) were studied. RESULTS: Infants with HbSS had a logarithmic decline in HbF parameters; at 24 months, the average HbF was 14.6%+/-7.3% and the % F cells was 64.7%+/-16.9%. The amount of HbF in each F cell (HbF per F cell) was <15 pg/cell, a suggested threshold for intracellular sickle polymerization, by age 12 months. Infants with HbSC had a more rapid decline: at 12 months the average % HbF was 12.2%+/-9.3%, the % F cells was 60.5%+/-18.7%, and the HbF per F cell was <10 pg/cell. CONCLUSIONS: By age 2 years, HbF parameters including the % HbF, % F cells, and the HbF per F cell decrease to levels insufficient to inhibit sickling. Pharmacologic intervention designed to enhance HbF production and prevent chronic organ damage should be considered during infancy.
PURPOSE: Fetal hemoglobin (HbF) is an important determinant in the clinical severity of patients with sickle cell disease. The physiologic decline in HbF parameters in a cohort of infants with sickle cell disease was investigated. PATIENTS AND METHODS: The percent HbF and F cells were quantitated, and the HbF per F cell was then calculated. One hundred thirty-eight blood samples from 44 infants with homozygous sickle cell anemia (HbSS) and 56 samples from 24 infants with sickle cell hemoglobin (HbSC) were studied. RESULTS:Infants with HbSS had a logarithmic decline in HbF parameters; at 24 months, the average HbF was 14.6%+/-7.3% and the % F cells was 64.7%+/-16.9%. The amount of HbF in each F cell (HbF per F cell) was <15 pg/cell, a suggested threshold for intracellular sickle polymerization, by age 12 months. Infants with HbSC had a more rapid decline: at 12 months the average % HbF was 12.2%+/-9.3%, the % F cells was 60.5%+/-18.7%, and the HbF per F cell was <10 pg/cell. CONCLUSIONS: By age 2 years, HbF parameters including the % HbF, % F cells, and the HbF per F cell decrease to levels insufficient to inhibit sickling. Pharmacologic intervention designed to enhance HbF production and prevent chronic organ damage should be considered during infancy.
Authors: Patrick T McGann; Omar Niss; Min Dong; Anu Marahatta; Thad A Howard; Tomoyuki Mizuno; Adam Lane; Theodosia A Kalfa; Punam Malik; Charles T Quinn; Russell E Ware; Alexander A Vinks Journal: Am J Hematol Date: 2019-06-12 Impact factor: 10.047
Authors: Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins Journal: Am J Hematol Date: 2017-09-28 Impact factor: 10.047
Authors: Emily Riehm Meier; Colleen Byrnes; Maxine Weissman; Pierre Noel; Naomi L C Luban; Jeffery L Miller Journal: Pediatr Blood Cancer Date: 2011-01 Impact factor: 3.167
Authors: Emily R Meier; Susan E Creary; Matthew M Heeney; Min Dong; Abena O Appiah-Kubi; Stephen C Nelson; Omar Niss; Connie Piccone; Maa-Ohui Quarmyne; Charles T Quinn; Kay L Saving; John P Scott; Ravi Talati; Teresa S Latham; Amanda Pfeiffer; Lisa M Shook; Alexander A Vinks; Adam Lane; Patrick T McGann Journal: Trials Date: 2020-11-27 Impact factor: 2.279